Photos: Dark Dark Dark's EP Release at the Cedar Cultural Center

Mantle cell lymphoma treatment reviewed. this web site mantle cell lymphoma

Blood Weekly March 11, 2004 2004 MAR 11 – (NewsRx.com & NewsRx.net) — The treatment of mantle cell lymphoma has been reviewed.

“During the last few years, new insights into the biology of mantle cell lymphoma have been obtained,” according to hematologists in Germany. “However, with a median survival of only 3 years, mantle cell lymphoma remains the lymphoma subtype with the poorest prognosis.” “At initial diagnosis most patients present with advanced Ann Arbor stage III or IV and conventional chemotherapy hardly alters the continuously declining survival curve,” noted G. Lenz and colleagues at the University of Munich.

“Recently, two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG) clearly confirmed the superiority of a combined immunochemotherapy,” they said. “In a randomized study of the European Mantle Cell Lymphoma Network, consolidation with myeloablative radiochemotherapy followed by autologous stem-cell transplantation improved the progression-free survival in patients younger than 65 years.” “However, relapses are still observed at a high frequency. Thus, new therapeutic strategies such as radioactively labeled antibodies or molecular targeting agents (e.g. Bortezomib or flavopiridol) are urgently warranted to further improve the clinical outcome of mantle cell lymphoma,” the researchers concluded. this web site mantle cell lymphoma

Lenz and coauthors published their study in the Annals of Hematology (Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol, 2004;83(2):71-77).

For more information, contact G. Lenz, University of Munich, Grosshadern Hospital, Department of Internal Medicine 3, Marchioninistr. 15, D-81377 Munich, Germany.

Publisher contact information for the journal Annals of Hematology is: Springer-Verlag, 175 Fifth Avenue, New York, NY 10010, USA.

The information in this article comes under the major subject areas of Hematology, Oncology, Pharmaceutical & Drug Development, Stem-Cell Transplantation and Transfusion Medicine.